Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Dec 11;12(12):CD004102.
doi: 10.1002/14651858.CD004102.pub3.

Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection)

Maite Vallejo  1 , Pedro Pa Reyes  1 , Mireya Martinez Garcia  2 , Alejandro G Gonzalez Garay  3
Affiliations
Meta-Analysis

Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection)

Maite Vallejo et al. Cochrane Database Syst Rev. .

Abstract

Background: People with Chagas disease may develop progressive and lethal heart conditions. Drugs to eliminate the parasite Trypanosoma cruzi (T cruzi) currently carry limited therapeutic value and are used in the early stages of the disease. Extending the use of these drugs to treat chronic chagasic cardiomyopathy (CCC) has also been proposed.

Objectives: To assess the benefits and harms of nitrofurans and trypanocidal drugs for treating late-stage, symptomatic Chagas disease and CCC in terms of blood parasite reduction or clearance, mortality, adverse effects, and quality of life.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and LILACS databases on 12 November 2019. We also searched two clinical trials registers, ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), on 3 December 2019.

Selection criteria: We included randomised controlled trials (RCTs) assessing trypanocidal drugs versus placebo or no treatment for late-stage, symptomatic Chagas disease and CCC.

Data collection and analysis: We conducted the reporting of the review according the standard Cochrane methods. Two review authors independently retrieved articles, performed data extraction, and assessed risk of bias. Any disagreements were resolved by a third review author. We contacted study authors for additional information.

Main results: We included two studies in this review update. One RCT randomly assigned 26 participants to benznidazole 5 mg/kg/day; 27 participants to nifurtimox 5 mg/kg/day; and 24 participants to placebo for 30 days. The second RCT, newly included in this update, randomised 1431 participants to benznidazole 300 mg/day for 40 to 80 days and 1423 participants to placebo. We also identified one ongoing study. Benznidazole compared to placebo At five-year follow-up, low quality of the evidence suggests that there may be a benefit of benznidazole when compared to placebo for clearance or reduction of antibody titres (risk ratio (RR) 1.25, 95% confidence interval (CI) 1.14 to 1.37; 1 trial; 1896 participants). We are uncertain about the effects of benznidazole for the clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays due to very limited evidence. Low quality of the evidence suggests that when compared to placebo, benznidazole may make little to no difference in the risk of heart failure (RR 0.89, 95% CI 0.69 to 1.14; 1 trial; 2854 participants) and ventricular tachycardia (RR 0.80, 95% CI 0.51 to 1.26; 1 trial; 2854 participants). We found moderate quality of the evidence that adverse events increase with benznidazole when compared to placebo (RR 2.52, 95% CI 2.09 to 3.03; 1 trial; 2854 participants). Adverse effects were observed in 23.9% of patients in the benznidazole group compared to 9.5% in the placebo group. The most frequent adverse effects were: cutaneous rash, gastrointestinal symptoms, and peripheral polyneuropathy. No data were available for the outcomes of pathological demonstration of tissue parasites and quality of life. Nifurtimox compared to placebo Data were only available for this comparison for the outcome clearance or reduction of antibody titres, and we are uncertain about the effect due to very limited evidence. Regarding adverse events, one RCT mentioned in a general manner that nifurtimox caused intense adverse events, without any quantification.

Authors' conclusions: There is insufficient evidence to support the efficacy of the trypanocidal drugs benznidazole and nifurtimox for late-stage, symptomatic Chagas disease and CCC.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest in this work.

MV: none known.

PAR: none known.

MMG: none known.

AGG: none known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1: Benznidazole versus placebo, Outcome 1: Clearance of antibody titres
1.2
1.2. Analysis
Comparison 1: Benznidazole versus placebo, Outcome 2: Clearance of parasitaemia, demonstrated by negative xenodiagnosis, blood culture, and/or molecular biology assays
1.3
1.3. Analysis
Comparison 1: Benznidazole versus placebo, Outcome 3: Clinical improvement
1.4
1.4. Analysis
Comparison 1: Benznidazole versus placebo, Outcome 4: Adverse effects
2.1
2.1. Analysis
Comparison 2: Nifurtimox versus placebo, Outcome 1: Clearance of antibody titres
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Coura 1997 {published data only}
    1. Coura JR, De Abreu L, Percy H, Willcox F, Petana W. A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical 1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009] - DOI - PubMed
Morillo 2015 {published data only}
    1. Morillo C, Marin-Neto J, Avezum A, Sosa-Estani S, Rassi A, Rosas F, et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine 2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574] - DOI - PubMed

References to studies excluded from this review

Aguiar 2012 {published data only}
    1. Aguiar C, Batista A, Pavan T, Almeida E, Guariento M, Wanderleyn J, et al. Serological profiles and evaluation of parasitaemia by PCR and blood culture in individuals chronically infected by Trypanosoma cruzi treated with benzonidazole. Tropical Medicine & International Health 2012;17(3):368-73. [DOI: 10.1111/j.1365-3156.2011.02936.x] - DOI - PubMed
Alvarez 2012 {published data only}
    1. Alvarez M, Vigliano C, Lococo B, Petti M, Bertocchi G, Viotti R. Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 2012;106(10):636-8. [DOI: 10.1016/j.trstmh.2012.07.010] - DOI - PubMed
Alvarez 2016 {published data only}
    1. Álvarez M, Hernández Y, Bertocchi G, Fernández M, Lococo B, Ramírez J, et al. New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: a pilot short-term follow-up study with adult patients. Antimicrobial Agents and Chemotherapy 2016;60:833–7. [DOI: 10.1128/AAC.00745-15] - DOI - PMC - PubMed
Bertocchi 2013 {published data only}
    1. Bertocchi GL, Vigliano C, Lococo B, Petti M, Viotti R. Clinical characteristics and outcome of 107 adult patients with chronic Chagas disease and parasitological cure criteria. Transactions of the Royal Society of Tropical Medicine and Hygiene 2013;107:372–6. [DOI: 10.1093/trstmh/trt029] - DOI - PubMed
Bestetti 2011 {published data only}
    1. Bestetti R, Cardinalli-Neto A. Antitrypanosomal therapy for chronic Chagas’ disease. New England Journal of Medicine 2011;364(26):2527-34. [DOI: 10.1056/NEJMc1108653] - DOI - PubMed
Braga 2000 {published data only}
    1. Braga M, Lauria-Pires L, Argalaraz E, Nascimento R, Teixeira A. Persistent infection in chronic Chagas disease patients treated with anti-trypanosoma cruzi nitroderivatives. Revista do Instituto de Medicina Tropical de Sao Paulo 2000;42:157-61. [DOI: 10.1590/s0036-46652000000300009] - DOI - PubMed
Bravo 2011 {published data only}
    1. Bravo I, Parra F, Nello C, Rodríguez-Bonfante C, Useche F, Bonfante-Cabarcas R. Prevalence of Trypanosoma cruzi antibodies and inflammatory markers in uncompensated heart failure. Revista da Sociedade Brasileira de Medicina Tropical 2011;44(6):691-6. [DOI: 10.1590/s0037-86822011000600008] - DOI - PubMed
Cancado 2002 {published data only}
    1. Cancado J. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Revista do Instituto de Medicina Tropical de Sao Paulo 2002;44:29-37. [DOI: 10.1590/S0036-46652002000100006 ] - PubMed
EQUITY 2019 {published data only}
    1. Villar J, Herrera V, Pérez J, Váquiro E, Castellanos Y, Vásquez S, et al. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial. Trials 2019;20(1):1-10. [DOI: 10.1186/s13063-019-3423-3] - DOI - PMC - PubMed
Fabbro 2000 {published data only}
    1. Fabbro de Suasnábar D, Arias E, Streiger M, Placenza M, Ingraramo M, Del Barco M, et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated Chagasic patients. Revista do Instituto de Medicina Tropical de Sao Paulo 2000;42:99-109. [DOI: 10.1590/s0036-46652000000200007] - DOI - PubMed
Lauria‐Pires 2000 {published data only}
    1. Lauria-Pires L, Braga M, Vexenat A, Nitz N, Simoes-Barbosa A, Tinoco D, et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. American Journal of Tropical Medicine and Hygiene 2000;63(3-4):111-8. [DOI: 10.4269/ajtmh.2000.63.111] - DOI - PubMed
Machado‐de‐Assis 2012 {published data only}
    1. Machado-de-Assis G, Silva A, Do Bem V, Bahia M, Martins-Filho O, Dias J, et al. Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests. Clinical and Vaccine Immunology 2012;19(8):1283-91. [DOI: 10.1128/CVI.00274-12] - DOI - PMC - PubMed
Moreira 2013 {published data only}
    1. Moreira O, Ramírez J, Velázquez E, Melo M, Lima-Ferreira C, Guhl F, et al. Towards the establishment of a consensus real-time qPCR to monitor Trypanosoma cruzi parasitaemia in patients with chronic Chagas disease cardiomyopathy: a substudy from the BENEFIT trial. Acta Tropica 2013;125(1):23-31. [DOI: 10.1016/j.actatropica.2012.08.020] - DOI - PubMed
Moreno 2010 {published data only}
    1. Moreno M, D'ávila D, Silva M, Galvão L, Macedo A, Chiari E, et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Memorias do Instituto Oswaldo Cruz 2010;105(7):918-24. [DOI: 10.1590/s0074-02762010000700014] - DOI - PubMed
Murcia 2010 {published data only}
    1. Murcia L, Carrilero B, Muñoz M, Iborra M, Segovia M. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas’ disease: a prospective study in a non-disease-endemic country. Journal of Antimicrobial Chemotherapy 2010;65(8):1759-64. [DOI: 10.1093/jac/dkq201] - DOI - PubMed
Perez‐Ayala 2010 {published data only}
    1. Pérez-Ayala A, Pérez-Molina J, Norman F, Navarro M, Monge-Maillo B, Díaz-Menéndez M, et al. Chagas disease in Latin American migrants: a Spanish challenge. Clinical Microbiology and Infection 2011;17(7):1108-13. [DOI: 10.1111/j.1469-0691.2010.03423.x] - DOI - PubMed
SaMiTrop 2018 {published data only}
    1. Cardoso C, Ribeiro A, Oliveira C, Oliveira L, Ferreira A, Bierrenbach A, et al. Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study. PLOS Neglected Tropical Diseases 2018;12:1-12. [DOI: 10.1371/journal.pntd.0006814] - DOI - PMC - PubMed
TRAENA 2015 {published data only}
    1. Riarte A. TRENA: Treatment with benznidazole in adult patients with chronic Chagas' disease. A phase 3 randomised clinical trial (RCT) double blinded [TRAENA: TRAtamiento con benznidazol EN pacientes Adultos con enfermedad de Chagas crónica. Un ensayo clínico aleatorizado (ECA) a doble ciego en Fase 3]. Informativo. Plataforma de investigación clínica en enfermedad de Chagas 2015;4:6-7.
Viotti 1994 {published data only}
    1. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serological evolution of patients with long-term follow-up. American Heart Journal 1994;127:151-62. [DOI: 10.1016/0002-8703(94)90521-5] - DOI - PubMed
Viotti 2006 {published and unpublished data}
    1. Viotti R, Viglian C, Lococo B, Bertochi G, Petti M, Alvarez M, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a non-randomised trial. Annals of Internal Medicine 2006;144:724-34. [DOI: 10.7326/0003-4819-144-10-200605160-00006] - DOI - PubMed

References to ongoing studies

NCT03191162 {unpublished data only}
    1. NCT03191162. Evaluation of different benznidazole regimens for the treatment of chronic Chagas disease (MULTIBENZ). clinicaltrials.gov/ct2/show/NCT03191162 (first received 19 June 2017).

Additional references

Andrade 2011
    1. Andrade J, Marin J, Paola A, Vilas-Boas F, Oliveira G, Bacal F, et al. I Latin American guidelines for the diagnosis and treatment of Chagas heart disease: executive summary. Arquivos Brasileiros de Cardiologia 2011;96:434-42. [DOI: 10.1590/s0066-782x2011000600002] - DOI - PubMed
Barretto 1990
    1. Barretto A, Azul L, Mady C, Ianni B, De Brito V, Belloti G, et al. Indeterminate form of Chagas' disease. A polymorphic disease [Forma indeterminada da doenca de chagas: Uma doenca polimorfica]. Arquivos Brasileiros de Cardiologia 1990;55:347-53. [PMID: ] - PubMed
Brener 1975
    1. Brener Z. Chemotherapy of Trypanosoma cruzi infections. Advances in Pharmacology 1975;13:1-44. [DOI: 10.1016/S1054-3589(08)60229-X] - DOI - PubMed
Briceno 2016
    1. Briceno L, Mosca W. What is not searched, it is difficult to find: Chagas' disease [Quello che non si cerca difficilmente si trova: la malattia di Chagas]. Giornale Italiano di Cardiologia 2016;17(5):343-7. [DOI: 10.1714/2252.24258] - DOI - PubMed
Cecere 1999
    1. Cecere M, Castañera M, Canale D, Chuit R, Gürtler R. Trypanosoma cruzi infection in Triatoma infestans and other triatomines: long-term effects of a control program in rural northwestern Argentina. Revista Panamericana de Salud Publica [Pan American Journal of Public Health] 1999;5:392-9. [DOI: 10.1590/s1020-49891999000500003] - DOI - PubMed
Chagas 1909
    1. Chagas C. New human trypanosomia. Studies on the morphology and evolutionary cycle of the Schizotrypanum cruzi n.gen., N.sp., ethiological adjunct of a new morbid entity of man [Nova tripanozomiaze humana. Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n.gen., n.sp., ajente etiolojico de nova entidade morbida do homem]. Memorias do Instituto Oswaldo Cruz 1909;1:159-218. [DOI: 10.1590/S0074-02761909000200008] - DOI
Cochrane Heart Group
    1. Cochrane Heart Group. Preferred method for handling continuous variables. www.heart.cochrane.org/Files/Handling%20continuous%20variables.pdf (accessed June 2005).
Contijo 1999
    1. Contijo E, Galvão L, Eloi-Santos S. Chagas disease: criteria of cure and prognosis. Memorias do Instituto Oswaldo Cruz 1999;94(Suppl 1):357-62. [DOI: 10.1590/S0074-02761999000700069] - DOI - PubMed
Coura 2009
    1. Coura J. Present situation and new strategies for Chagas disease chemotherapy: a proposal. Memorias do Instituto Oswaldo Cruz 2009;104(4):549-54. [DOI: 10.1590/s0074-02762009000400002] - DOI - PubMed
de Andrade 1996
    1. Andrade A, Zicker F, Oliveira R, Almeida S, Luquetti A, Travassos L, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348(9039):1407-13. [DOI: 10.1016/s0140-6736(96)04128-1] - DOI - PubMed
Dias 2009
    1. Dias J. Elimination of Chagas disease transmission: prospectives. Memorias do Instituto Oswaldo Cruz 2009;104(Suppl 1):41-5. [DOI: 10.1590/S0074-02762009000900007] - DOI - PubMed
Follman 1992
    1. Follman D, Elliot P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45:769-73. [DOI: 10.1016/0895-4356(92)90054-q] - DOI - PubMed
Fumadó 2014
    1. Fumadó V, Juncosa T, Posada E, Fisa R, Gállego M, Gascón J. Paediatric Chagas in a non-endemic area [Chagas pediátrico en zona no endémica]. Enfermedades Infecciosas y Microbiologia Clinica 2014;32(5):293-6. [DOI: 10.1016/j.eimc.2013.04.024] - DOI - PubMed
Gobbi 2014
    1. Gobbi F, Angheben A, Anselmi M, Postiglione C, Repetto E, Buonfrate D, et al. Profile of Trypanosoma cruzi infection in a tropical medicine reference center, Northern Italy. PLOS Neglected Tropical Diseases 2014;8(12):e3361. [DOI: 10.1371/journal.pntd.0003361] - DOI - PMC - PubMed
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime) GRADEpro GDT. Version accessed prior to 10 December 2020. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.
Grant 1989
    1. Grant I, Gold J, Wittner M, Tanowitz H, Nathan C, Mayer K, et al. Transfusion-associated acute Chagas disease acquired in the United States. Annals of Internal Medicine 1989;111:849. [DOI: 10.7326/0003-4819-111-10-849] - DOI - PubMed
Harry 2000
    1. Harry M, Lema F, Romaña C. Chagas' disease challenge. Lancet 2000;355:236. [DOI: 10.1016/S0140-6736(05)72114-0] - DOI - PubMed
Higgins 2002
    1. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58. [DOI: 10.1002/sim.1186] - DOI - PubMed
Higgins 2003
    1. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557] - DOI - PMC - PubMed
Higgins 2011a
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011b
    1. Higgins J, Altman D, Gøtzsche P, Jüni P, Moher D, Oxman A, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;18(343):d5928. [DOI: 10.1136/bmj.d5928 ] - PMC - PubMed
Hozo 2005
    1. Hozo S, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 2005;5(13):1-10. [DOI: 10.1186/1471-2288-5-13] - PMC - PubMed
Imai 2015
    1. Imai K, Maeda T, Sayama Y, Osa M, Mikita K, Kurane I, et al. Chronic Chagas disease with advanced cardiac complications in Japan: case report and literature review. Parasitology International 2015;64(5):240-2. [DOI: 10.1016/j.parint.2015.02.005] - DOI - PubMed
Kraus 2009
    1. Kraus J, Verlinde C, Karimi M, Lepesheva G, Gelb M, Buckner F. Rational modification of a candidate cancer drug for use against Chagas disease. Journal of Medicinal Chemistry 2009;52(6):1639-47. [DOI: 10.1021/jm801313t] - DOI - PMC - PubMed
Kubata 2002
    1. Kubata B, Kabututu Z, Nozaki T, Munday C, Fukuzumi S, Ohkubo K, et al. A key role for old yellow enzyme in the metabolism of drugs by Tripanosoma cruzi. Journal of Experimental Medicine 2002;196:1241-51. [DOI: 10.1084/jem.20020885] - DOI - PMC - PubMed
Laucella 2009
    1. Laucella S, Mazliah D, Bertocchi G, Alvarez M, Cooley G, Viotti R, et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clinical Infectious Diseases 2009;49(11):1675-84. [DOI: 10.1086/648072] - DOI - PMC - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Lopez‐Monteon 2019
    1. López-Monteon A, Dumonteil E, Ramos-Ligonio A. More than a hundred years in the search for an accurate diagnosis for Chagas disease: current panorama and expectations. In: Rodriguez-Morales AJ, editors(s). Current Topics in Neglected Tropical Diseases. IntechOpen, 2019:4-14. [DOI: 10.5772/intechopen.86567] - DOI
Mady 2008
    1. Mady C, Ianni B, Souza J. Benznidazole and Chagas disease: can an old drug be the answer to an old problem? Expert Opinion on Investigational Drugs 2008;17(10):1427-33. [DOI: 10.1517/13543784.17.10.1427] - DOI - PubMed
Monteón 1995
    1. Monteón V, Guzman-Bracho C, Floriani-Verdugo J, Ramos-Echavaria A, Velasco-Castrejón O, Reyes-López PA. Serological diagnosis of Chagas disease: self-sufficiency and interlaboratory concordance [Diagnóstico serológico de la enfermedad de Chagas: autosuficiencia y concordancia interlaboratorios]. Salud Publica de Mexico 1995;37:232-5. [PMID: ] - PubMed
Monteón‐Padilla 1999
    1. Monteón-Padilla V, Hernández-Becerril N, Guzmán-Bracho C, Rosales-Encina J, Reyes-López PA. American Trypanosomiasis (Chagas' disease) and blood banking in Mexico City: seroprevalence and its potential transfusional transmission risk. Archives of Medical Research 1999;30:393-8. [DOI: 10.1016/S0188-4409(99)00062-4] - DOI - PubMed
Moretti 1998
    1. Moretti E, Cervetta L, Basso B, Castro I, Santamarina N. Chronic Chagas' disease: effects of treatment on the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens [Enfermedad de Chagas crónica: efectos del tratamiento en los niveles de anticuerpos hacia antígenos crudos y semipurificados del Trypanosoma cruzi]. Boletin Chileno de Parasitologia 1998;53:3-9. [PMID: ] - PubMed
Nickerson 1989
    1. Nickerson P, Our P, Schroeder M, Sekla L, Johnston J. Transfusion-associeted Trypanosoma cruzi infection in a non-endemic area. Annals of Internal Medicine 1989;111:851. [DOI: 10.7326/0003-4819-111-10-851] - DOI - PubMed
Oliveira‐Filho 1989
    1. Oliveira-Filho A. Cost-effectiveness analysis in Chagas' disease vector's control intervention. Memorias do Instituto Oswaldo Cruz 1989;84 (Suppl IV):409-17. [DOI: 10.1590/S0074-02761989000800074] - DOI
Perman 2017
    1. Perman G. Cluster clinical trials [Ensayos clínicos por conglomerados]. EVIDENCIA Actualizacion en la Practica Ambulatoria 2017;20(1):22-5.
Pinto 1995
    1. Pinto Dias JC. Natural history of Chagas disease [História natural da doenca de Chagas]. Arquivos Brasileiros de Cardiologia 1995;65:359-65. - PubMed
Ramos 2012
    1. Ramos J, Torrús D, Amador C, Jover F, Pérez-Chacón F, Ponce Y, et al. Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain. Pathogens and Global Health 2012;106(6):340-5. [DOI: 10.1179/2047773212Y.0000000039] - DOI - PMC - PubMed
Ramsey 2014
    1. Ramsey J, Elizondo-Cano M, Sanchez-González G, Peña-Nieves A, Figueroa-Lara A. Opportunity cost for early treatment of Chagas disease in Mexico. PLOS Neglected Tropical Diseases 2014;8(4):e2776. [DOI: 10.1371/journal.pntd.0002776] - DOI - PMC - PubMed
Rassi 2007
    1. Rassi A, Luquetti A, Rassi A Jr, Rassi G, Rassi S, Da Silva IG, et al. Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. American Journal of Tropical Medicine and Hygiene 2007;76(1):58-61. [PMID: ] - PubMed
Rassi 2010
    1. Rassi A Jr, Rassi A, Marin-Neto J. Chagas disease. Lancet 2010;375(9723):1388-402. [DOI: 10.1016/S0140-6736(10)60061-X] - DOI - PubMed
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Robertson 2016
    1. Robertson L, Devleesschauwer B, Alarcón B, Noya González O, Torgerson P. Trypanosoma cruzi: time for international recognition as a foodborne parasite. PLOS Neglected Tropical Diseases 2016;10(6):e000465. [DOI: 10.1371/journal.pntd.0004656] - DOI - PMC - PubMed
Rodriguez‐Coura 2002
    1. Rodriguez-Coura J, Castro S. A critical review on Chagas disease chemotherapy. Memorias do Instituto Oswaldo Cruz 2002;97:3-24. [DOI: 10.1590/s0074-02762002000100001] - DOI - PubMed
Rojas 1999
    1. Rojas A, Ferro E, Ferreira M, Simancas L. Chagas disease vector control through different intervention modalities in endemic localities of Paraguay. Bulletin of the World Health Organization 1999;77:331-9. [PMID: ] - PMC - PubMed
Sales 2017
    1. Sales P, Molina I, Fonseca S, Sánchez-Montalvá A, Salvador F, Corrêa-Olivera R, et al. Experimental and clinical treatment of Chagas disease: a review. American Journal of Tropical Medicine and Hygiene 2017;97(5):1289-303. [DOI: 10.4269/ajtmh.16-0761] - DOI - PMC - PubMed
Salomao 2016
    1. Salomao K, Menna-Barreto R, Castro S. Stairway to heaven or hell? Perspectives and limitations of Chagas disease chemotherapy. Current Topics in Medicinal Chemistry 2016;16(20):2266-89. [DOI: 10.2174/1568026616666160413125049] - DOI - PubMed
Sbaraglini 2016
    1. Sbaraglini M, Vanrell M, Bellera C, Benaim G, Carrillo C, Talevi A, et al. Neglected tropical protozoan diseases: drug repositioning as a rational option. Current Topics in Medicinal Chemistry 2016;16(19):2201-22. [DOI: 10.2174/1568026616666160216154309] - DOI - PubMed
Schijman 2011
    1. Schijman A, Bisio M, Orellana L, Sued M, Duffy T, Mejia A, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLOS Neglected Tropical Diseases 2011;5(1):e931. [DOI: 10.1371/journal.pntd.0000931] - DOI - PMC - PubMed
Schmunis 1994
    1. Schmunis G. American trypanosomiasis as a public health problem. In: Chagas' Disease and the Nervous System. Washington, DC: Pan American Health Organization, World Health Organization, 1994:3-29.
Schmunis 1999
    1. Schmunis G. Prevention of transfusional Trypanosoma cruzi infection in Latin America. Memorias do Instituto Oswaldo Cruz 1999;94(Suppl 1):93-101. [DOI: 10.1590/s0074-02761999000700010] - DOI - PubMed
Schmuñis 2013
    1. Schmuñis G. Status of and cost of Chagas disease worldwide. Lancet Infectious Diseases 2013;13(4):283-4. [DOI: 10.1016/S1473-3099(13)70032-X] - DOI - PubMed
Schofield 1999
    1. Schofield C, Dias J. The southern cone initiative against Chagas disease. Advances in Parasitology 1999;42:1-27. [DOI: 10.1016/s0065-308x(08)60147-5] - DOI - PubMed
Schofield 2006
    1. Schofield C, Jannin J, Salvatella R. The future of Chagas disease control. Trends in Parasitology 2006;22(12):583-8. [DOI: 10.1016/j.pt.2006.09.011] - DOI - PubMed
Schunemann 2013
    1. Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations.. The GRADE Working Group. 2013. [Available from guidelinedevelopment. org/handbook.]
Segura 1994
    1. Segura M, Molina E, Basombrio M. Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment. Memorias do Instituto Oswaldo Cruz 1994;89:213-6. [DOI: 10.1590/s0074-02761994000200017] - DOI - PubMed
Sosa 1998
    1. Sosa S, Segura E, Ruiz A, Velazquez E, Porcel B, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. American Journal of Tropical Medicine and Hygiene 1998;59:526-9. [DOI: 10.4269/ajtmh.1998.59.526] - DOI - PubMed
Sterne 2000
    1. Sterne J, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology 2000;53:1119–29. [DOI: 10.1016/s0895-4356(00)00242-0] - DOI - PubMed
Sterne 2001
    1. Sterne J, Matthias E, Smith G. Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;323:189-208. [DOI: 10.1136/bmj.323.7304.101 ] - PMC - PubMed
Stoppani 1999
    1. Stoppani A. The chemotherapy of Chagas disease [Quimioterapia de la enfermedad de Chagas]. Medicina 1999;59(Suppl 2):147-65. [PMID: ] - PubMed
Tanowitz 1992
    1. Tanowitz H, Morris S, Factor S, Weiss L, Wittner M. Parasitic disease of the heart I: acute and chronic Chagas' disease. Cardiovascular Pathology 1992;1:7-15. [DOI: 10.1016/1054-8807(92)90004-8] - DOI - PubMed
Tarleton 2014
    1. Tarleton RL, Gürtler RE, Urbina JA, Ramsey J, Viotti R. Chagas disease and the London declaration on neglected tropical diseases. PLOS Neglected Tropical Diseases 2014;10(8):e3219. [DOI: 10.1371/journal.pntd.0003219] - DOI - PMC - PubMed
Urbina 1999
    1. Urbina J. Parasitological cure of Chagas disease: is it possible? Is it relevant? Memorias do Instituto Oswaldo Cruz 1999;94(Suppl 1):349-55. [DOI: 10.1590/s0074-02761999000700068] - DOI - PubMed
Urbina 2009
    1. Urbina J. Ergosterol biosynthesis and drug development for Chagas disease. Memorias do Instituto Oswaldo Cruz 2009;104(Suppl 1):311-8. [DOI: 10.1590/s0074-02762009000900041] - DOI - PubMed
Urbina 2015
    1. Urbina J. Recent clinical trials for the etiological treatment of Chronic Chagas disease: advances, challenges and perspectives. Journal of Eukaryotic Microbiology 2015;62(1):149-56. [DOI: 10.1111/jeu.12184] - DOI - PubMed
Valerio‐Sallent 2012
    1. Valerio-Sallent L, Roure S, Basile L, Ballesteros L, Sabrià M, Rodrigo C, Grupo Metropolitano de estudio del Chagas. A clinical and epidemiological study of the Trypanosoma cruzi infected population in the north metropolitan area of Barcelona [Un estudio clínico-epidemiológico de la población infectada por Trypanosoma cruzi en la zona metropolitana norte de Barcelona]. Revista Clinica Espanola 2012;212(7):329-36. [DOI: 10.1016/j.rce.2012.03.017] - DOI - PubMed
Villar 2002
    1. Villar J, Villar L, Marin-Neto J, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No: CD003463. [DOI: 10.1002/14651858.CD003463] - DOI - PubMed
Villar 2014
    1. Villar JC, Perez JG, Cortes OL, Riarte A, Pepper M, Marin-Neto JA, et al. Trypanocidal drugs for chronic symptomatic Trypanosoma cruzi infection. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No: CD003463. [DOI: 10.1002/14651858.CD003463.pub2] - DOI - PMC - PubMed
WHO 1991
    1. World Health Organization. Control of Chagas' disease. Report of a WHO Expert Committee. WHO Technical Report Series No. 811. Geneva: World Health Organization, 1991. - PubMed
WHO 2015
    1. WHO/Department of control of neglected tropical diseases. Investing to overcome the global impact of neglected tropical diseases: Third WHO report on neglected tropical diseases 2015. Vol. 3. World Health Organization, 2015.
WHO 2017
    1. WHO/Department of Control of Neglected Tropical Diseases. Fourth WHO report on neglected tropical diseases. Vol. 1. Geneva: World Health Organization, 2017.
Yun 2009
    1. Yun O, Lima M, Ellman T, Chambi W, Castillo S, Flevaud L, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontières. PLOS Neglected Tropical Diseases 2009;3(7):e488. [DOI: 10.1371/journal.pntd.0000488] - DOI - PMC - PubMed

Publication types

MeSH terms